Press release from PR Newswire
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results
Tuesday, February 28, 2012
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results16:30 EST Tuesday, February 28, 2012Investor Conference Call to be held Thursday, March 1, 2012 at 8:30am ESTNEW YORK, Feb. 28, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease, today announced that a conference call will be held on Thursday, March 1, 2012, at 8:30 a.m. EST to discuss the Company's fourth quarter and year-end 2011 financial results and business outlook for 2012. Ron Bentsur, Chief Executive Officer of Keryx, will host the call. In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.Keryx will announce its financial results for this period in a press release to be issued prior to the call.ABOUT KERYX BIOPHARMACEUTICALS, INC. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.KERYX CONTACT:?Lauren Fischer?Director - Investor Relations?Keryx Biopharmaceuticals, Inc.?Tel: 212.531.5965?E-mail: email@example.comSOURCE Keryx Biopharmaceuticals, Inc.